Skip to main
RNXT
RNXT logo

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx has demonstrated notable revenue growth, recording $422K in Q2, an increase from $197K in Q1. The company anticipates strong revenue expansion, projecting revenue levels of $1.3 million in 2025 and $4.5 million in 2026, indicating a positive trajectory in financial performance. The firm's focus on innovative cancer treatment options, supported by its proprietary Trans-Arterial Micro-Perfusion therapy platform, positions it favorably within the biopharmaceutical sector, addressing high unmet medical needs.

Bears say

RenovoRx's financial performance reveals persistent challenges, with a revenue of $0.3 million and a net loss of $2.9 million consistently reported, indicating an inability to generate meaningful revenue amid substantial operational costs. The company’s focus on targeting pancreatic cancer, which has a severely low 5-year survival rate of only 12%, underscores the high-risk nature of its therapeutic goals and market demand. Given these financial metrics and the competitive landscape in cancer therapies, concerns about the company's sustainability and growth potential overshadow any perceived positive elements.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.